An evaluation of treatment and management strategies in ADHD

Are stimulants really that effective compared to other available options?

Abstract

Background: Stimulant medications are the first-line treatment for Attention-Deficit/Hyperactivity Disorder (ADHD), but their increasing use and potential long-term physiological costs warrant reevaluation. Objective: This narrative review examines the effectiveness of stimulants compared to non-stimulant medications and non-pharmacological interventions, considering both short-term symptom relief and long-term developmental outcomes. Methods: Data from the Multimodal Treatment Study (MTA) 14-month and 16-year follow-ups were synthesized with contemporary meta-analyses and cohort studies. Key metrics included Standardized Mean Differences (SMD) for efficacy and Incidence Rate Ratios (IRR) for safety. Results: Stimulants show high acute efficacy for core symptoms (SMD 0.81–1.10), but long-term MTA data reveal no significant symptom reduction by early adulthood. Extended use carries costs, including adult height suppression (2.55 cm in consistent users) and increased cardiovascular risk (IRR 1.41) within six months. Behavioral therapies (BT) have lower blinded efficacy for core symptoms (SMD 0.12) but better outcomes in functional domains such as organizational skills (SMD 0.85). Combined treatment maintains symptom control at lower stimulant doses (31.2 mg vs. 37.7 mg/day). Non-stimulants like Atomoxetine offer moderate benefit (Hedges’ g ≈ −0.48) with different safety profiles, including higher somnolence but less height suppression. Conclusion: Effective ADHD management requires moving from symptom-focused pharmacological monotherapy to a multimodal, lifespan-oriented approach. Behavioral interventions provide essential support for functional outcomes. Combined strategies remain the clinical gold standard, optimizing efficacy while potentially reducing long-term physiological risks of stimulants.